Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy

Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP), a passive polyclonal antibody therapeutic agent, has had mixed clinical results. Although antibody neutralization is the predominant approach to benchmarking CCP efficacy, CCP may also influence the evolution of the endogenous antibody r...

Descripción completa

Detalles Bibliográficos
Autores principales: Herman, Jonathan D., Wang, Chuangqi, Burke, John Stephen, Zur, Yonatan, Compere, Hacheming, Kang, Jaewon, Macvicar, Ryan, Taylor, Sabian, Shin, Sally, Frank, Ian, Siegel, Don, Tebas, Pablo, Choi, Grace H., Shaw, Pamela A., Yoon, Hyunah, Pirofski, Liise-anne, Julg, Boris D., Bar, Katharine J., Lauffenburger, Douglas, Alter, Galit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9595358/
https://www.ncbi.nlm.nih.gov/pubmed/36351430
http://dx.doi.org/10.1016/j.xcrm.2022.100811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9595358/
https://www.ncbi.nlm.nih.gov/pubmed/36351430
http://dx.doi.org/10.1016/j.xcrm.2022.100811

Ejemplares similares